Dose capping enoxaparin is unjustified and denies patients with acute coronary syndromes a potentially effective treatment

Chest. 2005 Jun;127(6):2288-9; author reply 2289-90. doi: 10.1378/chest.127.6.2288.
No abstract available

Publication types

  • Comment
  • Comparative Study
  • Letter

MeSH terms

  • Acute Disease
  • Angina, Unstable / diagnosis
  • Angina, Unstable / drug therapy*
  • Angina, Unstable / mortality
  • Anticoagulants / adverse effects
  • Anticoagulants / pharmacokinetics
  • Anticoagulants / therapeutic use*
  • Biological Availability
  • Clinical Trials as Topic
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Enoxaparin / adverse effects
  • Enoxaparin / pharmacokinetics
  • Enoxaparin / therapeutic use*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Maximum Tolerated Dose*
  • Myocardial Infarction / diagnosis
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / mortality
  • Risk Assessment
  • Severity of Illness Index
  • Survival Analysis
  • Treatment Outcome

Substances

  • Anticoagulants
  • Enoxaparin